BioWorld

Feb. 21, 2008

View Archived Issues

Pfizer $195M Deal for Encysive Called a 'Good Deal' For Both

First Working Pancreatic Beta Cells Derived from ESCs

Bioheart Squeezes Out IPO Window with Meager $5.8M

Antisense Licenses MS Drug to Teva for $2M Up Front

Other News To Note

Clinic Roundup

Acceleron, Celgene in Potential $1.8B Bone Loss Collaboration

When it came to signing its first biotech collaboration since being founded in 2003, Acceleron Pharma Inc. made sure it was a big one. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...